½ÃÀ庸°í¼­
»óǰÄÚµå
1494343

ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¿¹Ãø(-2028³â) : Áö¿ªº° ºÐ¼® - Àç·áº°, Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°

North America Flowable Hemostats Market Forecast to 2028 - Regional Analysis - by Material, Product, Application, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 122 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº 2022³â 4¾ï 9,474¸¸ ´Þ·¯¿¡¼­ 2028³â 7¾ï 4,249¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2028³â±îÁö ¿¬Æò±Õ 7.0%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç° Çõ½ÅÀ» °¡Á®¿À´Â R&D Ȱµ¿ÀÌ ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀ» ÁÖµµ

ÁöÇ÷Á¦ Á¦Ç°Àº ÇコÄÉ¾î »ê¾÷¿¡¼­ ³ôÀº ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. Áö³­ ¸î ³â µ¿¾È ¸¹Àº ÁöÇ÷Á¦°¡ °³¹ßµÇ¾î ¿©·¯ °¡Áö ¼ö¼ú¿¡ »ç¿ëµÇ¾ú½À´Ï´Ù. ¿¬±¸ °³¹ßÀÚµéÀº ÁýÁßÀûÀÎ ¿¬±¸ °³¹ß Ȱµ¿À» ¼öÇàÇÏ¿© Á¦Ç° Çõ½ÅÀ» °¡Á®¿Ô½À´Ï´Ù. ¿¹¸¦ µé¾î, 2019³â 12¿ù, ¿¡Æ¼ÄÜ(Á¸½¼¾ØµåÁ¸½¼ ÀÇ·á±â±â ±â¾÷)ÀÇ ½ÅÁ¦Ç° "SURGIFLO ÁöÇ÷ ¸ÅÆ®¸¯½º"´Â ¼ö¼ú Áß ÃâÇ÷À» ¸ØÃß°Ô ÇÏ´Â SURGIFLOW À¯µ¿¼º ÁöÇ÷ Á¦Ç°À¸·Î FLOSEAL(Baxter»ç)º¸´Ù ´õ ºü¸£°Ô ÁöÇ÷ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2018³â 1¿ù, ÁöÇ÷ ÀåÄ¡ °³¹ß ¹× ÆÇ¸Å ¾÷üÀÎ Z-Medica, LLC´Â »ý¸íÀ» ±¸Çϰí Àü±¹ º´¿øÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ QuikClot ControlÀ» Ãâ½ÃÇßÀ¸¸ç, QuikClot ControlÀº Class III ¶Ç´Â Class IV ÃâÇ÷À» º¸À̴ ȯÀÚÀÇ ³»Àå°­ ³» ÃâÇ÷À» ÀϽÃÀûÀ¸·Î Á¶ÀýÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ, ¼ö¼ú »óó³ª ¿Ü»ó µî ½É°¢ÇÑ ÃâÇ÷ÀÌ ÀÖ´Â »óóÀÇ ÃâÇ÷À» Á¶ÀýÇÏ´Â µ¥¿¡µµ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç° Çõ½ÅÀ¸·Î À̾îÁö´Â R&D Ȱµ¿Àº ¿¹Ãø ±â°£ µ¿¾È Àüü À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ź·ÂÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå °³¿ä

ÁöÇ÷Á¦ Á¦Ç°Àº ÀÇ·á »ê¾÷¿¡¼­ ³ôÀº ¼ö¿ä°¡ ÀÖ½À´Ï´Ù. Áö³­ ¸î ³â µ¿¾È ¸¹Àº ÁöÇ÷Á¦ Á¦Ç°ÀÌ °³¹ßµÇ¾î ¿©·¯ °¡Áö ¼ö¼ú¿¡ »ç¿ëµÇ¾ú½À´Ï´Ù. ¿¬±¸ °³¹ßÀÚµéÀº ÁýÁßÀûÀÎ ¿¬±¸ °³¹ß Ȱµ¿À» ¼öÇàÇÏ¿© Á¦Ç° Çõ½ÅÀ» °¡Á®¿Ô½À´Ï´Ù. ¿¹¸¦ µé¾î, 2019³â 12¿ù, ¿¡Æ¼ÄÜ(Á¸½¼¾ØµåÁ¸½¼ ÀÇ·á±â±â ±â¾÷)ÀÇ ½ÅÁ¦Ç° "SURGIFLO ÁöÇ÷ ¸ÅÆ®¸¯½º"´Â ¼ö¼ú Áß ÃâÇ÷À» ¸ØÃß°Ô ÇÏ´Â SURGIFLOW À¯µ¿¼º ÁöÇ÷ Á¦Ç°À¸·Î FLOSEAL(Baxter»ç)º¸´Ù ´õ ºü¸£°Ô ÁöÇ÷ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2018³â 1¿ù, ÁöÇ÷ ÀåÄ¡ °³¹ß ¹× ÆÇ¸Å ¾÷üÀÎ Z-Medica, LLC´Â »ý¸íÀ» ±¸Çϰí Àü±¹ º´¿øÀÇ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ QuikClot ControlÀ» Ãâ½ÃÇßÀ¸¸ç, QuikClot ControlÀº Class III ¶Ç´Â Class IV ÃâÇ÷À» º¸À̴ ȯÀÚÀÇ ³»Àå°­ ³» ÃâÇ÷À» ÀϽÃÀûÀ¸·Î Á¶ÀýÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ, ¼ö¼ú »óó³ª ¿Ü»ó µî ½É°¢ÇÑ ÃâÇ÷ÀÌ ÀÖ´Â »óóÀÇ ÃâÇ÷À» Á¶ÀýÇÏ´Â µ¥¿¡µµ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¦Ç° Çõ½ÅÀ¸·Î À̾îÁö´Â R&D Ȱµ¿Àº ¿¹Ãø ±â°£ µ¿¾È Àüü À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀÇ ¼ºÀå¿¡ ź·ÂÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¸ÅÃâ ¹× 2028³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¼¼ºÐÈ­

ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº Àç·á, Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

Àç·áº°·Î ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº ¼Ò Á©¶óƾ°ú µÅÁö Á©¶óƾÀ¸·Î ³ª´µ¸ç, 2022³â ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ ¼Ò Á©¶óƾ ºÐ¾ß°¡ Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Á¦Ç°º°·Î ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº º¹ÇÕ ÁöÇ÷Á¦, ¼öµ¿ ÁöÇ÷Á¦, ´Éµ¿ ÁöÇ÷Á¦·Î ±¸ºÐµÇ¸ç, 2022³â ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ º¹ÇÕ ÁöÇ÷Á¦ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº ÀÏ¹Ý ¼ö¼ú, ½ÉÀå ¼ö¼ú, Ç÷°ü ¼ö¼ú, Á¤Çü¿Ü°ú, ½Å°æ ¹× ôÃß ¼ö¼ú, ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ ÀÏ¹Ý ¼ö¼ú ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ºÏ¹Ì ÁöÇ÷Á¦ ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ·Î ±¸ºÐµÇ¸ç, 2022³â ºÏ¹Ì ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ º´¿ø ¹× Ŭ¸®´Ð ½ÃÀåÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ºÐ·ùµË´Ï´Ù. ¹Ì±¹Àº 2022³â ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.

Baxter International Inc, Ethicon(Johnson & Johnson), Pfizer Inc, Teleflex Incorporated, 3D Matrix Medical Technology, Biom'up, Aegis Lifesciences´Â ºÏ¹Ì À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ Áß ÇϳªÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ¿äÁ¡

Á¦3Àå Á¶»ç ¹æ¹ý

  • Ä¿¹ö ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - ½ÃÀå »óȲ

  • °³¿ä
  • ºÏ¹Ì PEST ºÐ¼®
    • ºÏ¹ÌÀÇ PEST ºÐ¼®
  • ºÏ¹ÌÀÇ Àü¹®°¡ÀÇ °ßÇØ

Á¦5Àå ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ºÎ»óÀ̳ª ¿Ü°ú¼ö¼ú Áõ°¡
    • ³ëÀÎ Àα¸ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼÷·Ã Àü¹®°¡ÀÇ ºÎÁ·°ú ºÒÃæºÐÇÑ »óȯ Á¤Ã¥
  • ½ÃÀå ±âȸ
    • º´¿ø¼ö¿Í ¼ö¼ú ¼¾ÅÍ ¼ö Áõ°¡
  • ÇâÈÄ µ¿Çâ
    • Á¦Ç° Çõ½ÅÀ¸·Î À̾îÁö´Â ¿¬±¸°³¹ß(R&D) Ȱµ¿
  • ¿µÇ⠺м®

Á¦6Àå À¯µ¿¼º ÁöÇ÷Á¦ ºÏ¹Ì ½ÃÀå ºÐ¼®

  • ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¸ÅÃâÀ̶ó°í ºÐ¼®

Á¦7Àå ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¸ÅÃâ ¿¹Ãø°ú ºÐ¼®

  • ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ºÐ¼® - ¼ÒÀ纰
  • ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : Àç·áº° Á¡À¯À²(2021³â, 2028³â)
  • ¼Ò Á©¶óƾ
    • ¼Ò Á©¶óƾ : ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø
  • µÅÁö Á©¶óƾ
    • µÅÁö Á©¶óƾ : ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø

Á¦8Àå À¯µ¿¼º ÁöÇ÷Á¦ ºÏ¹Ì ½ÃÀå : Á¦Ç°º°

  • ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : Á¦Ç°º° Á¡À¯À²(2021³â, 2028³â)
  • ÄÞºñ³×ÀÌ¼Ç ÁöÇ÷Á¦
    • ÄÞºñ³×ÀÌ¼Ç ÁöÇ÷Á¦ ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø
  • ÆÐ½Ãºê ÁöÇ÷Á¦
    • ÆÐ½Ãºê ÁöÇ÷Á¦ ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø
  • Ȱ¼ºÇü ÁöÇ÷Á¦
    • Ȱ¼º ÁöÇ÷Á¦ : ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø

Á¦9Àå À¯µ¿¼º ÁöÇ÷Á¦ ºÏ¹Ì ½ÃÀå - ¿ëµµº°

  • ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¿ëµµº° Á¡À¯À²(2021³â, 2028³â)
  • ÀϹݿܰú
    • ÀϹݿܰú ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø
  • ½ÉÀå¿Ü°ú
    • ½ÉÀå¿Ü°ú °³¿ä
    • ½ÉÀå¿Ü°ú ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø
  • Ç÷°ü¿Ü°ú
    • Ç÷°ü¿Ü°ú °³¿ä
    • Ç÷°ü¿Ü°ú ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø
  • Á¤Çü¿Ü°ú
    • Á¤Çü¿Ü°ú °³¿ä
    • Á¤Çü¿Ü°ú ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø
  • ½Å°æ¡¤Ã´Ã߿ܰú
    • ½Å°æ¿Ü°ú¿Í ôÃ߿ܰú ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø
  • ±âŸ
    • ±âŸ
    • ±âŸ ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : 2028³â±îÁö ¸ÅÃâ°ú ¿¹Ãø

Á¦10Àå À¯µ¿¼º ÁöÇ÷Á¦ ºÏ¹Ì ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° Á¡À¯À²(2021³â, 2028³â)
  • º´¿ø ¹× Áø·á¼Ò
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

Á¦11Àå ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå ¸ÅÃâ°ú 2028³â±îÁö ¿¹Ãø : ±¹°¡º° ºÐ¼®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ

Á¦12Àå ºÏ¹ÌÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - ¾÷°è »óȲ

  • À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀÇ ¼ºÀå Àü·«(%)
  • À¯±âÀû Àü°³
  • ¹«±âÀû Àü°³

Á¦13Àå ±â¾÷ °³¿ä

  • Baxter International Inc
  • Ethicon(Johnson & Johnson)
  • Pfizer Inc.
  • Teleflex Incorporated
  • 3-D Matrix Medical Technology
  • Biom'up
  • Aegis Lifesciences

Á¦14Àå ºÎ·Ï

ksm 24.06.20

The North America flowable hemostats market is expected to grow from US$ 494.74 million in 2022 to US$ 742.49 million by 2028. It is estimated to grow at a CAGR of 7.0% from 2022 to 2028.

Research and Development (R&D) Activities Leading to Product Innovations Fuel North America Flowable Hemostats Market

Hemostat products are high in demand in the healthcare industry. Over the past several years, many hemostat products have been developed and utilized in several surgical procedures. Researchers are carrying out intensive research and development activities resulting in product innovations. For Instance, In December 2019, Ethicon's (Johnson & Johnson Medical Device Companies) new product, "SURGIFLO Hemostatic Matrix." SURGIFLOW flowable hemostatic product stops bleeding while performing surgery and is faster than FLOSEAL (manufactured by Baxter). Furthermore, In January 2018, Z-Medica, LLC, a leading developer and marketer of hemostatic devices introduced QuikClot Control+ which can help save lives and fill the unmet need of hospitals across the country. QuikClot Control+ is indicated for temporary control of internal organ space bleeding for patients displaying class III or class IV bleeding. It may even be used to control severe bleeding wounds such as surgical wounds and traumatic injuries. Thus, research and development activities leading to product innovations are predicted to deliver an impetus for the growth of the overall flowable hemostats market during the forecast period.

North America Flowable Hemostats Market Overview

Hemostat products are high in demand in the healthcare industry. Over the past several years, many hemostat products have been developed and utilized in several surgical procedures. Researchers are carrying out intensive research and development activities resulting in product innovations. For Instance, In December 2019, Ethicon's (Johnson & Johnson Medical Device Companies) new product, "SURGIFLO Hemostatic Matrix." SURGIFLOW flowable hemostatic product stops bleeding while performing surgery and is faster than FLOSEAL (manufactured by Baxter). Furthermore, In January 2018, Z-Medica, LLC, a leading developer and marketer of hemostatic devices introduced QuikClot Control+ which can help save lives and fill the unmet need of hospitals across the country. QuikClot Control+ is indicated for temporary control of internal organ space bleeding for patients displaying class III or class IV bleeding. It may even be used to control severe bleeding wounds such as surgical wounds and traumatic injuries. Thus, research and development activities leading to product innovations are predicted to deliver an impetus for the growth of the overall flowable hemostats market during the forecast period.

North America Flowable Hemostats Market Revenue and Forecast to 2028 (US$ Million)

North America Flowable Hemostats Market Segmentation

The North America flowable hemostats market is segmented into material, product, application, end user, and country.

Based on material, the North America flowable hemostats market is bifurcated into bovine gelatin & porcine gelatin. The bovine gelatin segment held a larger share of the North America flowable hemostats market in 2022.

In terms of product, the North America flowable hemostats market is segmented into combination hemostats, passive hemostats, and active hemostats. The combination hemostats segment held the largest share of the North America flowable hemostats market in 2022.

Based on Application, the North America flowable hemostats market is categorized into general surgery, cardiac surgery, vascular surgery, orthopedic surgery, neuro and spine surgery, and others. The general surgery segment held the largest share of the North America flowable hemostats market in 2022.

Based on end user, the North America flowable hemostats market is segmented into hospitals and clinics, ambulatory surgery centers, and others. The hospitals and clinics segment held the largest share of the North America flowable hemostats market in 2022.

By country, the North America flowable hemostats market is categorized into the US, Canada, and Mexico. The US dominated the North America flowable hemostats market in 2022.

Baxter International Inc, Ethicon (Johnson & Johnson), Pfizer Inc, Teleflex Incorporated, 3-D Matrix Medical Technology, Biom'up, and Aegis Lifesciences are some of the leading companies operating in the North America North America flowable hemostats market.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 North America Flowable Hemostats Market - By Material
    • 1.3.2 North America Flowable Hemostats Market - By Product
    • 1.3.3 North America Flowable Hemostats Market - By Application
    • 1.3.4 North America Flowable Hemostats Market - By End User
    • 1.3.5 North America Flowable Hemostats Market - By Country

2. Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Flowable Hemostats Market - Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis
    • 4.2.1 North America PEST Analysis
  • 4.3 North America Experts Opinion

5. North America Flowable Hemostats Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increasing Number of Injuries and Surgical Procedures
    • 5.1.2 Rising Geriatric Population
  • 5.2 Market Restraints
    • 5.2.1 Shortage of Skilled Professionals and Poor Reimbursement Policies
  • 5.3 Market Opportunities
    • 5.3.1 Increasing Number of Hospitals and Surgical Centers
  • 5.4 Future Trends
    • 5.4.1 Research and Development (R&D) Activities Leading to Product Innovations
  • 5.5 Impact Analysis

6. Flowable Hemostats Market - North America Analysis

  • 6.1 North America Flowable Hemostats Market Revenue Forecast & Analysis

7. North America Flowable Hemostats Market Revenue Forecast & Analysis

  • 7.1 North America Flowable Hemostats Market Analysis - By Material
  • 7.2 North America Flowable Hemostats Market Share, by Material, 2021 and 2028 (%)
  • 7.3 Bovine Gelatin
    • 7.3.1 Overview
    • 7.3.2 Bovine Gelatin: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Porcine Gelatin
    • 7.4.1 Overview
    • 7.4.2 Porcine Gelatin: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)

8. North America Flowable Hemostats Market- By Product

  • 8.1 Overview
  • 8.2 North America Flowable Hemostats Market Share, by Product, 2021 and 2028 (%)
  • 8.3 Combination Hemostat
    • 8.3.1 Overview
    • 8.3.2 Combination Hemostat: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Passive Hemostat
    • 8.4.1 Overview
    • 8.4.2 Passive Hemostat: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Active Hemostat
    • 8.5.1 Overview
    • 8.5.2 Active Hemostat: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)

9. North America Flowable Hemostats Market- By Application

  • 9.1 Overview
  • 9.2 North America Flowable Hemostats Market Share, by Application, 2021 and 2028 (%)
  • 9.3 General Surgery
    • 9.3.1 Overview
    • 9.3.2 General Surgery: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.4 Cardiac Surgery
    • 9.4.1 Overview
    • 9.4.2 Cardiac Surgery: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Vascular Surgery
    • 9.5.1 Overview
    • 9.5.2 Vascular Surgery: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.6 Orthopedic Surgery
    • 9.6.1 Overview
    • 9.6.2 Orthopedic Surgery: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.7 Neuro and Spine Surgery
    • 9.7.1 Overview
    • 9.7.2 Neuro and Spine Surgery: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)
  • 9.8 Others
    • 9.8.1 Overview
    • 9.8.2 Others: North America Flowable Hemostats Market- Revenue and Forecast to 2028 (US$ Million)

10. North America Flowable Hemostats Market Analysis - By End User

  • 10.1 Overview
  • 10.2 North America Flowable Hemostats Market Share, by End User, 2021 and 2028, (%)
  • 10.3 Hospitals and Clinics
    • 10.3.1 Overview
    • 10.3.2 Hospitals and Clinics: North America Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.4 Ambulatory Surgery Centers
    • 10.4.1 Overview
    • 10.4.2 Ambulatory Surgery Centers: North America Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
  • 10.5 Others
    • 10.5.1 Overview
    • 10.5.2 Others: North America Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)

11. North America Flowable Hemostats Market Revenue and Forecasts to 2028 - Country Analysis

  • 11.1 North America: Flowable Hemostats Market
    • 11.1.1 Overview
    • 11.1.2 North America: Flowable Hemostats Market, by Country, 2022 & 2028 (%)
      • 11.1.2.1 US: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.1.1 Overview
      • 11.1.2.2 US: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.2.1 US: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.2.2 US: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.2.3 US: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.2.4 US: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)
      • 11.1.2.3 Canada: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.3.1 Overview
        • 11.1.2.3.2 Canada: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.3.3 Canada: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.3.4 Canada: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.3.5 Canada: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.3.6 Canada: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)
      • 11.1.2.4 Mexico: Flowable Hemostats Market - Revenue and Forecast to 2028 (US$ Million)
        • 11.1.2.4.1 Overview
        • 11.1.2.4.2 Mexico: Flowable Hemostats Market - Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.3 Mexico: Flowable Hemostats Market, by Material- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.4 Mexico: Flowable Hemostats Market, by Product- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.5 Mexico: Flowable Hemostats Market, by Application- Revenue and Forecast to 2028 (USD Million)
        • 11.1.2.4.6 Mexico: Flowable Hemostats Market, End User - Revenue and Forecast to 2028 (USD Million)

12. North America Flowable Hemostats Market-Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in the Flowable Hemostats Market (%)
  • 12.3 Organic Developments
    • 12.3.1 Overview
  • 12.4 Inorganic Developments
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Baxter International Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Ethicon (Johnson & Johnson)
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Pfizer Inc.
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Teleflex Incorporated
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 3-D Matrix Medical Technology
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Biom'up
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Aegis Lifesciences
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 North America Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦